PODD
Insulet Corporation
$269.2
Earnings Summary
Revenue | $295.4Mn |
Net Profits | $27.8Mn |
Net Profit Margins | 9.41% |
PE Ratio | 516.56 |
Highlights
Insulet Corporation’s revenue jumped 17.08% since last year same period to $295.4Mn in the Q1 2022. On a quarterly growth basis, Insulet Corporation has generated -4% fall in its revenue since last 3-months.
Insulet Corporation’s net profit jumped +Inf% since last year same period to $27.8Mn in the Q1 2022. On a quarterly growth basis, Insulet Corporation has generated -4.79% fall in its net profits since last 3-months.
Insulet Corporation’s net profit margin jumped +Inf% since last year same period to 9.41% in the Q1 2022. On a quarterly growth basis, Insulet Corporation has generated -0.83% fall in its net profit margins since last 3-months.
Insulet Corporation’s price-to-earnings ratio after this Q1 2022 earnings stands at 516.56.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Insulet Corporation post its latest quarter earnings
EPS Estimate Current Quarter | 0.22 |
EPS Estimate Current Year | 0.22 |
Highlights
Insulet Corporation’s earning per share (EPS) estimates for the current quarter stand at 0.22 - a -4.35% fall from last quarter’s estimates.
Insulet Corporation’s earning per share (EPS) estimates for the current year stand at 0.22.
Key Ratios
Key ratios of the Insulet Corporation post its Q1 2022 earnings
Earning Per Share (EPS) | 0.4 |
Return on Assets (ROA) | 0.03 |
Return on Equity (ROE) | 0.08 |
Dividend Per Share (DPS) | 0 |
Highlights
Insulet Corporation’s earning per share (EPS) jumped +Inf% since last year same period to 0.4 in the Q1 2022. This indicates that the Insulet Corporation has generated +Inf% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Insulet Corporation’s return on assets (ROA) stands at 0.03.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Insulet Corporation’s return on equity (ROE) stands at 0.08.
Insulet Corporation declared 0 dividend per share during the earnings announcement for Q1 2022.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2022-05-06 | 0.23 | 0.4 | 73.91% |
Company Information
Insulet Corporation , headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.
Organisation | Insulet Corporation |
Headquarters | Acton, Massachusetts, US |
Employees | 1.9K |
Industry | Health Technology |
CEO | Shacey Petrovic |